


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compounds of the formula I



in which

R denotes Hal, $-C\equiv C-H$, $-C\equiv C-A$ or OA,


R¹ denotes H, =O, Hal, A, OH, OA, A-COO-, Ph-(CH₂)ₙ-COO-, cycloalkyl-(CH₂)ₙ-COO-, A-CONH-, A-CONA-, Ph-CONA-, N₃, NH₂, NO₂, CN, COOH, COOA, CONH₂, CONHA, CON(A)₂, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA or =CF₂,

R² denotes H or A,

Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, OH or Hal,

R³ denotes H, Hal or A,

R⁴ denotes $-C_6H_4-(CH_2)_n-NR^5R^{5'}$, $-C(=NR^5)NR^5R^{5'}$,



R⁵, R⁵' each, independently of one another, denote H or A,

A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,


Hal denotes F, Cl, Br or I,

- n denotes 0, 1, 2 or 3,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
2. (Original) Compounds according to Claim 1, in which
R denotes Hal or $\text{-C}\equiv\text{C-H}$,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
3. (Currently Amended) Compounds according to Claim 1 ~~or 2~~, in which
 R^1 denotes H, =O, Hal, A, OH or OA,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
4. (Currently Amended) Compounds according to ~~one or more of Claims 1-3~~
Claim 1, in which
 R^1 denotes OH or OA,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
5. (Currently Amended) Compounds according to ~~one or more of Claims 1-4~~
Claim 1, in which
 R^3 denotes H or Hal,
and the pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
6. (Currently Amended) Compounds according to ~~one or more of Claims 1-5~~
Claim 1, in which
 R^5 , $\text{R}^{5'}$ each, independently of one another, denote H or alkyl having 1, 2, 3, 4,
5 or 6 C atoms,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

7. (Original) Compounds according to Claim 1, in which

- R denotes Hal or $-C\equiv C-H$,
 R^1 denotes OH or OA
 R^2 denotes H or A,
 R^3 denotes H or Hal,
 R^4 denotes $-C_6H_4-(CH_2)_n-NR^5R^{5'}$, $-C(=NR^5)NR^4R^{5'}$,



R^5 , $R^{5'}$ each, independently of one another, denote H or A,

- A denotes unbranched, branched or cyclic alkyl having 1-12 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
Hal denotes F, Cl, Br or I,
n denotes 0, 1, 2 or 3,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

8. (Original) Compounds according to Claim 1 selected from the group

N-1-[(4-chlorophenyl)]-N-2-{{[4-(2-{dimethylaminomethyl}phenyl)-phenyl]}}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-{{[4-(2-{dimethylaminomethyl}phenyl)-phenyl]}}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-{{[2-fluoro-4-(2-{dimethylaminomethyl}phenyl)phenyl]}}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-{{[2-fluoro-4-(2-{dimethylaminomethyl}phenyl)phenyl]}}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(4-(2-dimethylaminomethylimidazol-1-yl)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(2-dimethylaminomethyl-imidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(2-dimethylamino-methylimidazol-1-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(4-(*N,N*-dimethylamidino)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(*N,N*-dimethylamidino)-phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-chlorophenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-1-[(4-ethynylphenyl)]-N-2-[(4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,


N-1-[(4-ethynylphenyl)]-N-2-[(2-fluoro-4-(1-methyl-4,5-dihydro-1*H*-imidazol-2-yl)phenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended) Process for the preparation of compounds of the formula I according to ~~Claims 1-8~~ Claim 1 and pharmaceutically usable derivatives,

solvates, salts and stereoisomers thereof, characterised in that


a) a compound of the formula II



in which R has the meaning indicated in Claim 1,

is reacted with a chloroformate derivative to give an intermediate carbamate derivative,

which is subsequently reacted with a compound of the formula III




in which

R¹, R², R³ and R⁴ have the meaning indicated in Claim 1,

or

b) a compound of the formula III

is reacted with a compound of the formula IV




in which

R has the meaning indicated in Claim 1,


or

c) a compound of the formula V



in which R³ and R⁴ have the meaning indicated in Claim 1,

is reacted with a compound of the formula VI



in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group
and

R, R¹ and R² have the meanings indicated in Claim 1,

and/or

a base or acid of the formula I is converted into one of its salts.

10. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 as inhibitors of coagulation factor Xa.
11. (Currently Amended) Compounds of the formula I according to ~~one or more of~~

~~Claims 1 to 9~~ Claim 1 as inhibitors of coagulation factor VIIa.

12. (Currently Amended) Medicaments comprising at least one compound of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
13. (Currently Amended) Medicaments comprising at least one compound of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
14. (Currently Amended) Use of compounds according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tinnitus, tumours, tumour diseases and/or tumour metastases.
15. (Currently Amended) Set (kit) consisting of separate packs of
 - (a) an effective amount of a compound of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,
 - and
 - (b) an effective amount of a further medicament active ingredient.
16. (Currently Amended) Use of compounds of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or pharmaceutically usable derivatives,

solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,

for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tinnitus, tumours, tumour diseases and/or tumour metastases,

in combination with at least one further medicament active ingredient.